Português

Abstract

Neisseria meningitidis is a pathogen that significantly impacts public health. Serogroup B poses a challenge in vaccine development due to the structural similarity between the capsular polysaccharide of the bacteria and the polysialic acid present in human brain tissue, which not only exhibits low immunogenicity but can also cause adverse reactions. Technological advancements have enabled the development of the recombinant-protein vaccines Bexsero and Trumenba against meningococcus B to induce a safe immune response. This study aimed to speculate about the impact Bexsero and Trumenba could have on the vaccination schedule in Brazil. It consisted of a literature review using articles collected from databases between the years 1985 to 2023. After comparison, it was demonstrated that the Bexsero vaccine contains multiple antigens (recombinant proteins and outer membrane antigens), providing broad age coverage and efficacy in children and adolescents, while Trumenba utilizes two variants of fHbp and is indicated for young adults, particularly in university outbreak settings. After the analyses in the United Kingdom and its inclusion in its national immunization program, the Bexsero vaccine emerges as a suitable  alternative for inclusion in the National Immunization Program of Brazil (PNI), it showed broader coverage and better efficacy, reducing the incidence of invasive meningococcal disease and its complications.